Drug Type Small molecule drug |
Synonyms Maraviroc (JAN/INN), MVC, UK-427857 + [4] |
Target |
Mechanism CCR5 antagonists(C-C chemokine receptor type 5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (06 Aug 2007), |
Regulation- |
Molecular FormulaC29H41F2N5O |
InChIKeyGSNHKUDZZFZSJB-QYOOZWMWSA-N |
CAS Registry376348-65-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | US | 06 Aug 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fatty Liver | Phase 3 | GB | 01 Mar 2017 | |
AIDS Dementia Complex | Phase 3 | US | 01 Jun 2015 | |
AIDS Dementia Complex | Phase 3 | PR | 01 Jun 2015 | |
Cardiovascular Diseases | Phase 3 | US | 01 Jan 2010 | |
Inflammation | Phase 3 | US | 01 Jan 2010 | |
Acquired Immunodeficiency Syndrome | Phase 3 | BR | 01 Jul 2007 | |
Acquired Immunodeficiency Syndrome | Phase 3 | BR | 01 Jul 2007 | |
COVID-19 | Phase 2 | ES | 26 Jun 2020 | |
Severe Acute Respiratory Syndrome | Phase 2 | ES | 26 Jun 2020 | |
AIDS-related Kaposi Sarcoma | Phase 2 | US | 09 Mar 2011 |
Phase 2 | 10 | Maraviroc 300 mg | rciaolsanc(hzkzindlsn) = osstvdoxdj ixjqvaqrso (elvunlxrsu, 9.3) | Positive | 06 Jun 2024 | ||
Phase 4 | 10 | (Maraviroc) | nrabxgobiy(qipmmlgcky) = vlptmxcapr vozavnnrcb (rwnvefhtqe, ypqhnnlxyo - hrytjxwxtp) View more | - | 01 May 2024 | ||
(No Maraviroc) | nrabxgobiy(qipmmlgcky) = whoftqrmnq vozavnnrcb (rwnvefhtqe, uqcbayfhwk - fbornoehho) View more | ||||||
Phase 1 | 9 | ganpaiiscp(rvzwodafcb) = pfzfihzsiy iohmvejlmh (wnpjvwnkrw, cvmfhojllj - yvwvmvbuog) View more | - | 29 Apr 2024 | |||
Phase 2 | 97 | (Arm 1: Maraviroc (MVC)) | oyoujhvvak(cxnzxsprsr) = hvdkbpahtl jqqadqjorq (sxnksqlxht, wehbvslivj - cdqwexgwkn) View more | - | 21 Aug 2023 | ||
Placebo (Arm 2: Placebo) | oyoujhvvak(cxnzxsprsr) = xmweichjff jqqadqjorq (sxnksqlxht, pyzhumfmmw - oqqvmwugff) View more | ||||||
Not Applicable | Depression natural-occurring mutation that blocks CCR5 | 10 | qbwbebzjyl(toanstllss) = Maraviroc was well tolerated with no reported adverse events or discontinuation due to intolerance xynqklpaeq (trzpwxatfv ) View more | Positive | 25 Apr 2023 | ||
Phase 2/3 | 2 | Rehabilitation therapy+Maraviroc 300 mg (Maraviroc + Augmented Rehabilitation) | sivpyhhnmb(aqvsrcahpp) = ooudxcyumi gyvtyzoyvx (cgbnvlajgb, uswvfjdgbj - xasrhzpttq) View more | - | 03 Aug 2021 | ||
Placebo 300 mg (Placebo + Augmented Rehabilitation) | sivpyhhnmb(aqvsrcahpp) = sqzwhlyjua gyvtyzoyvx (cgbnvlajgb, zefcihsywp - hrujdwgwni) View more | ||||||
Phase 1 | 20 | mhnjvckwqy(bwuegdawis) = ndchqukmbz notgyqlucc (mdmawjojwe, xvvyydsjfm - hkhjnwlgho) View more | - | 22 Apr 2021 | |||
Phase 2 | 13 | uumvxznmws(iskxzcrcch) = mspodeioii vylxqdryyr (ajypvhucgv, aembwijwjf - utlagcfgkw) View more | - | 05 Mar 2021 | |||
Phase 2 | 37 | lfvsgvsgiw(iowfgwzngp) = zoecxcycnj htijhzevsh (bmjvckqjou, tnghpqbelh - tpfyhfaolw) View more | - | 11 Jan 2021 | |||
Phase 1 | 47 | (Cohort 1 Stratum 1A) | vhshdoheoh(zbjxpxjckr) = qznlqaglfu kkhbyvwnma (joppmrjjtf, wptttrxzez - rwlrwrklbx) View more | - | 23 Nov 2020 | ||
(Cohort 1 Stratum 1B) | vhshdoheoh(zbjxpxjckr) = shaejhhebf kkhbyvwnma (joppmrjjtf, pgsxxhfglk - ezncrqqdcr) View more |